Literature DB >> 11269749

Improved immunoturbidimetric assay for cystatin C.

A V Lewis1, T J James, J B McGuire, R P Taylor.   

Abstract

An immunoturbidimetric assay for cystatin C was optimized with respect to assay imprecision. After investigating the optimum pH, polyethylene glycol concentration and specimen volume, two modifications were introduced: an increase in specimen volume to 25 microL; and an extension of the pre-incubation period to 240 s. These modifications produced an assay with between-batch imprecision (coefficient of variation, n = 10 or 11) ranging from 3-9% at 0.72 mg/L to 1.3% at 5.29 mg/L. The assay was susceptible to interference from lipaemia and haemolysis but not bilirubinaemia in both the original and modified protocol. Extending the pre-incubation to 240 s improved tolerance to common interferences and retained assay applicability in the routine clinical setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11269749     DOI: 10.1258/0004563011900399

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  3 in total

1.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05

2.  Effectiveness of intravenous infusion of N-acetylcysteine in cirrhotic patients undergoing major abdominal surgeries.

Authors:  Eman Sayed Ibrahim; Ahmed Sharawy
Journal:  Saudi J Anaesth       Date:  2015 Jul-Sep

3.  Predicting the development of acute kidney injury in liver cirrhosis--an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers.

Authors:  A J Slack; M J W McPhail; M Ostermann; M Bruce; R Sherwood; R Musto; T Dew; G Auzinger; W Bernal; J O'Grady; M A Heneghan; K Moore; J A Wendon
Journal:  Aliment Pharmacol Ther       Date:  2013-04-12       Impact factor: 8.171

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.